{"analyses":[{"ciLowerLimit":"0.70","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.96","groupDescription":"Stratification factors: Enrollment stage, PD-L1 status, Bajorin risk score/presence of liver metastases, and investigator choice of chemotherapy.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0073","pValueComment":"inverse normal combination","paramType":"Hazard Ratio (HR)","paramValue":"0.82","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"6.24","upperLimit":"7.00","value":"6.34"},{"groupId":"OG001","lowerLimit":"6.51","upperLimit":"8.34","value":"8.18"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"400"},{"groupId":"OG001","value":"451"}],"units":"Participants"}],"description":"PFS is defined as the time from randomization to the first documented disease progression as determined by the investigator with the use of RECIST v1.1, or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received blinded placebo matched to atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG000","title":"Placebo+Gemcitabine+Carboplatin/Cisplatin"},{"description":"Participants received blinded atezolizumab in combination with open-label platinum-based chemotherapy (gemcitabine with either cisplatin or carboplatin).","id":"OG001","title":"Atezolizumab+Gemcitabine+Carboplatin/Cisplatin"}],"paramType":"MEDIAN","populationDescription":"The ITT population was defined as all participants randomized to the Atezolizumab+Gemcitabine+Carboplatin/Cisplatin arm or the Placebo+Gemcitabine+Carboplatin/Cisplatin arm in Stages 1 and 2, whether or not the assigned study treatment was received.","reportingStatus":"POSTED","timeFrame":"Baseline up to first documented disease progression or death, whichever occurs first (up to approximately 35 months)","title":"Investigator Assessed Progression-Free Survival (PFS) in the Placebo+Gemcitabine+Carboplatin/Cisplatin Arm Versus Atezolizumab +Gemcitabine+Carboplatin/Cisplatin Arm","type":"PRIMARY","unitOfMeasure":"Months"}